SuspendedNot Applicable

The Effects of Inositol on Glucose Metabolism in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis

Stopped: Difficulties in enrollment and patient compliance

Italy30 participantsStarted 2022-12-23

Plain-language summary

The study aims to evaluate the effects of an oral supplementation based on inositols and alpha-lactalbumin on principals metabolic parameters in patients with metabolic syndrome at risk of cardiac fibrosis

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

At least 3 of the following inclusion criteria: * triglycerides levels ≥ 150 mg/dL * HDL ≤ 40 mg/dL * Fasting glycemia \> 100 mg/dL \<126 mg/dl * Systolic Pressure ≥ 130 mmHg or Diastolic pressure ≥ 85 mmHg * Hip circumference \> 102 cm in men or 88 cm in women

What they're measuring

Body weight

Timeframe: Four time points: changes in body weight (kg) from the baseline to 30, 90, 180 days

Trial details

NCT IDNCT05689710

SponsorLo.Li.Pharma s.r.l

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-01

View on ClinicalTrials.gov More Metabolic Syndrome trials